A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) (Current study; NCT05500222). Accessed on 01/10/2024, 11:00 a.m. at